Pharmaceutical - Anti-virals, Licensing

Filter

Current filters:

Anti-viralsLicensing

Popular Filters

1 to 25 of 29 results

ViiV Healthcare links with Janssen to investigate single-tablet regimen for maintenance treatment of HIV-1

ViiV Healthcare links with Janssen to investigate single-tablet regimen for maintenance treatment of HIV-1

12-06-2014

ViiV Healthcare today announced that they have entered into an agreement with Janssen R&D Ireland, a…

Anti-viralsEdurantGlaxoSmithKlineJanssenJohnson & JohnsonLicensingPharmaceuticalResearchTivicayViiV Healthcare

PaxVax signs R&D deal with UC San Diego to develop herpes vaccine

PaxVax signs R&D deal with UC San Diego to develop herpes vaccine

11-06-2014

Privately-held California, USA-based specialty vaccine firm PaxVax has entered into a research and development…

Anti-viralsLicensingPaxVaxPharmaceuticalResearchVaccines

Ukraine government introduces compulsory licensing for pharma products

Ukraine government introduces compulsory licensing for pharma products

23-12-2013

Leading global pharmaceutical producers may suffer significant losses in Ukraine, as the country’s…

Anti-viralsAntibiotics and Infectious diseasesEastern EuropeLicensingOncologyPatentsPharmaceuticalUkraine

Janssen gains rights to Ph II hepatitis C candidate from GSK

08-10-2013

Janssen Pharmaceuticals has acquired the investigational compound GSK2336805, an NS5a replication complex…

Anti-viralsGlaxoSmithKlineGSK2336805JanssenJohnson & JohnsonLicensingPharmaceutical

Roche in up to $422.5 million deal with Inovio Pharma

11-09-2013

Swiss drug major Roche (ROG: SIX) has signed an exclusive, worldwide license agreement with US drug developer…

Anti-viralsINO-1800INO-5150Inovio PharmaceuticalsLicensingOncologyPharmaceuticalRoche

Immunocore in multi-million deal with GlaxoSmithKline on ImmTACs

09-07-2013

Oxford, UK-based biotech firm Immunocore, focused on developing novel biological drugs called ImmTACs…

Anti-viralsBiotechnologyGlaxoSmithKlineImmunocoreLicensingOncologyPharmaceuticalResearch

BioLineRx collaborates with Chinese firm on hep C drug BL-8030

11-06-2013

Israeli drug developer BioLineRx (TASE: BLRX) has signed an out-licensing agreement with Jiangsu Chia-tai…

Anti-viralsAsia-PacificBioLineRxBiotechnologyBL-8030Chia-tai Tianqing PharmaceuticalLicensingPharmaceutical

Bristol-Myers gets added indication from US FDA for Sustiva; signs second deal with Ambrx

06-05-2013

US pharma major Bristol-Myers Squibb (NYSE: BMY) says that the US Food and Drug Administration has approved…

AmbrxAnti-viralsBiotechnologyBristol-Myers SquibbCardio-vascularDiabetesLicensingNorth AmericaPharmaceuticalRegulationSustiva

Bristol-Myers Squibb signs up with another partner for daclatasvir, Merck & Co; latter expands deal with Xenon

23-04-2013

US pharma giant Merck & Co (NYSE: MRK) has entered into a non-exclusive agreement with drug major Bristol-Myers…

Anti-viralsBristol-Myers SquibbCardio-vasculardaclatasvirLicensingMerck & CoMK-5172PharmaceuticalResearchXenon Pharmaceuticals

Roche teams up with Ascletis on hep C treatments for China

15-04-2013

Roche (ROG: SIX) has entered a collaboration with Ascletis Pharmaceuticals, a USA- and China-based biotech…

Anti-viralsAscletis PharmaceuticalsAsia-PacificBiotechnologydanoprevirLicensingMarkets & MarketingPharmaceuticalResearchRoche

Merck & Co in-licenses portfolio targeting HCMV from AiCuris for up to $570 million

16-10-2012

US pharma giant Merck & Co (NYSE: MRK) has entered into an exclusive worldwide licensing agreement with…

AiCurisAnti-viralsletermovirLicensingMerck & CoPharmaceutical

Novartis restructures deal with Idenix Pharmaceuticals

01-08-2012

USA-based Idenix Pharmaceuticals (Nasdaq: IDIX) says that Swiss drug major Novartis (NOVN: VX) has restructured…

Anti-viralsIdenix PharmaceuticalsLicensingNovartisPharmaceuticaltelbivudine

Merck & Co in-licenses Chimerix antiviral; Fiocruz to make ARVs in Africa

24-07-2012

USA-based Chimerix, a venture-funded biotech focused on developing novel oral antivirals, has announced…

Anti-viralsChimerixCMX001CMX157FiocruzGlobalLicensingMarkets & MarketingMerck & CoPharmaceuticalRest of the World

Research news: dolutegravir; TD-1211; and synaptic modulators

11-07-2012

UK pharma giant GlaxoSmithKline (LSE: GSK) and Japanese drugmaker Shionogi (TYO: 4507) have reported…

Anti-viralsdolutegravirGalenea CorpGastro-intestinalsGlaxoSmithKlineLicensingNeurologicalPharmaceuticalRegulationResearchShionogiTD-1211TheravanceZonegran

Teva gets rights to BioAlliance's Sitavig in Israel

14-06-2012

French drugmaker BioAlliance Pharma (Euronext Paris: BIO) has signed an exclusive license agreement for…

Anti-viralsBioAlliance PharmaLicensingPharmaceuticalRest of the WorldSitavigTeva Pharmaceutical Industries

Bristol-Myers expands hepatitis C accord with Medivir and Janssen

18-04-2012

Swedish infectious disease drug developer Medivir AB (OMX: MVIR) said yesterday that its development…

Anti-viralsBristol-Myers SquibbdaclatasvirJanssenJohnson & JohnsonLicensingMedivirPharmaceuticalResearch

Enanta Pharma in $440 HCV licensing deal with Novartis

22-02-2012

USA-based discovery and development company Enanta Pharmaceuticals yesterday signed an exclusive collaboration…

Anti-viralsEnanta PharmaceuticalsLicensingNovartisPharmaceutical

BioLineRx in-licenses BL-8020, an oral hepatitis C treatment

26-01-2012

Israeli biopharma company BioLineRx (Nasdaq: BLRX) says it has signed a worldwide, exclusive license…

Anti-viralsBioLineRxGenoscienceLicensingPharmaceutical

Dendreon cashes in Victrelis royalty

08-12-2011

US pharma company Dendreon (Nasdaq: DNDN) says that it has agreed to sell for $125 million in cash its…

Anti-viralsBiotechnologyDendreonFinancialLicensingMerck & CoOncologyPharmaceuticalProvengeVictrelis

1 to 25 of 29 results

Back to top